Beam Therapeutics Inc. (BEAM)

Quarterly Report Filed: 2026-05-07

Key Insights

• The filing contains multiple contingent consideration liabilities and success payment obligations related to license agreements (Harvard, Broad, Lilly), indicating significant future payment obligations tied to development and regulatory milestones that could materially impact cash flow.
• Evidence of capital raising activities including underwritten public offerings and at-the-market (ATM) offerings through Jefferies LLC suggests the company is actively managing its cash position to fund R&D operations, which is typical for pre-commercial or early-stage biotech companies.
• The extensive fair value measurement disclosures across multiple investment holdings (US Treasury securities, corporate equity securities, commercial paper) indicate a substantial investment portfolio that provides financial flexibility but also suggests the company is managing significant cash reserves.
• Multiple equity incentive plans (2019 plans for employees and ESPP) referenced with activity in Q1 2026 show ongoing equity compensation usage, which may indicate dilution to shareholders but is standard for biotech talent retention.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Current Report Filed: 2026-05-07

Key Insights

• Beam Therapeutics filed an 8-K on May 7, 2026 to announce Q1 2026 financial results for the quarter ended March 31, 2026, indicating the company is actively reporting operational performance to shareholders.
• The filing is a routine earnings announcement with no material events, special disclosures, or significant corporate actions reported beyond standard financial results disclosure.
• John Evans, identified as Chief Executive Officer, signed the filing, confirming continued leadership stability at the company as of the filing date.
• The press release referenced in Exhibit 99.1 contains the detailed financial results but is furnished rather than filed, meaning it carries limited liability implications under securities law.

Sentiment: Neutral Significance: 2/10

View Original Filing →

Insider Trading Filed: 2026-04-06

Key Insights

• Insider John M. Evans, CEO of Beam Therapeutics, has automatically sold 30,078 shares to cover tax withholding obligations upon the vesting of restricted stock units, suggesting a potential focus on managing his personal tax liabilities.
• Evans also holds an indirect beneficial ownership of 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, indicating a long-term investment in the company.
• The reported transactions were executed pursuant to a Rule 10b5-1 trading plan, providing a structured approach to insider trading that can help mitigate concerns around potential insider information.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-06

Key Insights

• The reporting person, Amy Simon, who is the Chief Medical Officer of Beam Therapeutics Inc. (BEAM), sold 6,700 shares of common stock on April 1, 2026 at a price of $24.58 per share. This appears to be a routine transaction to cover tax withholding obligations upon the vesting of restricted stock units.
• The reporting person holds a total of 102,735 shares of BEAM common stock, including 183 and 138 shares acquired through the company's employee stock purchase plan in 2025 and 2026, respectively.
• The share sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, indicating a pre-planned and non-discretionary nature of the transaction.

Sentiment: Neutral Significance: 3/10

View Original Filing →

Insider Trading Filed: 2026-04-06

Key Insights

• Bethany J. Cavanagh, the SVP of Finance and Treasurer at Beam Therapeutics Inc., has conducted an automatic sale of 3,242 shares of common stock on April 1, 2026 to cover tax withholding obligations upon the vesting of certain restricted stock units.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Cavanagh on August 9, 2024, indicating a pre-planned transaction.
• Cavanagh's remaining beneficial ownership of 51,171 shares represents her ongoing commitment and alignment with the company's long-term success.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-06

Key Insights

• The reporting person, Christine Bellon, who is the Chief Legal Officer of Beam Therapeutics Inc., sold 5,956 shares of the company's common stock on April 1, 2026 to cover tax withholding obligations upon the vesting of certain restricted stock units.
• The sale of shares was part of a pre-arranged Rule 10b5-1 trading plan, indicating the transaction was non-discretionary and likely not a signal of the reporting person's sentiment about the company's prospects.
• The number of shares beneficially owned by the reporting person following the transaction remains significant at 109,711 shares, suggesting they continue to have a substantial stake in the company.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-06

Key Insights

• Insider Giuseppe Ciaramella, the President of Beam Therapeutics, sold 11,810 shares of common stock on April 1, 2026 to cover tax withholding obligations on vested restricted stock units.
• The sale was made pursuant to a previously adopted 10b5-1 trading plan, suggesting the transactions were pre-planned and not driven by discretionary trading.
• Ciaramella still holds a significant position of 218,406 shares in Beam Therapeutics, indicating his continued commitment to the company.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-02

Key Insights

• Insider Giuseppe Ciaramella, President of Beam Therapeutics Inc., acquired 40,000 restricted stock units (RSUs) on 2026-03-31, which will vest in four equal installments over the next four years.
• This RSU grant indicates Ciaramella's continued commitment and confidence in Beam Therapeutics' long-term growth and development.
• The insider transaction provides a positive signal to investors about the company's prospects, as the President is willing to hold a significant equity stake.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-02

Key Insights

• Christine Bellon, the Chief Legal Officer of Beam Therapeutics, acquired 20,000 restricted stock units (RSUs) on 03/31/2026, demonstrating her commitment to the company.
• Bellon's RSUs vest in four equal installments over the next four years, aligning her long-term incentives with the company's performance.
• This insider transaction suggests Bellon's confidence in Beam Therapeutics' future prospects and her alignment with shareholder interests.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-02

Key Insights

• Bethany J. Cavanagh, the SVP of Finance and Treasurer at Beam Therapeutics Inc., has acquired 20,000 shares of the company's common stock through restricted stock units (RSUs).
• This acquisition of shares aligns the interests of the reporting person with those of the company and its shareholders.
• The reporting person's total beneficial ownership of Beam Therapeutics shares has increased to 54,813 following this transaction.

Sentiment: Positive Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-02

Key Insights

• The Chief Medical Officer of Beam Therapeutics Inc. (BEAM) acquired 31,750 shares of the company's common stock through restricted stock units (RSUs) granted under the 2019 Equity Incentive Plan.
• The RSUs vest in four equal installments on the first four anniversaries of the grant date, subject to the reporting person's continued service with the company.
• This insider transaction suggests the Chief Medical Officer's confidence in the company's future and alignment with shareholder interests through equity-based compensation.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-04-02

Key Insights

• Sravan Kumar Emany, the Chief Financial Officer of Beam Therapeutics Inc. (BEAM), acquired 31,750 shares of the company's common stock through restricted stock units (RSUs) that vested on March 31, 2026.
• The RSUs represent the contingent right to receive one share of BEAM's common stock, with the RSUs vesting in four equal installments on the first four anniversaries of the grant date.
• This insider transaction suggests that the CFO has confidence in the company's long-term prospects and is aligning his interests with those of shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Current Report Filed: 2026-03-05

Key Insights

• Beam Therapeutics has terminated its license agreement with Bio Palette Co., Ltd., which was related to the company's base editing technology. This termination was mutual and part of Bio Palette's planned dissolution.
• Prior to the termination, Beam activated a standby license agreement with Kobe University, ensuring the company maintains exclusivity over the licensed patents in the event of the Bio Palette license termination.
• The termination of the Bio Palette agreement does not appear to have a significant impact on Beam's operations, as the company has secured the necessary intellectual property rights through the Kobe University standby license.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-02-26

Key Insights

• The reporting person, Giuseppe Ciaramella, who is the President of Beam Therapeutics Inc. (BEAM), exercised 35,000 stock options and immediately sold the same number of shares at a weighted average price of $32.0012, reflecting a profit of $15.0012 per share.
• The reported transaction was made pursuant to a Rule 10b5-1 trading plan, indicating a pre-planned sale of shares by the insider.
• The insider still holds 190,216 shares of BEAM common stock after the reported transaction, suggesting they continue to maintain a significant ownership stake in the company.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Annual Report Filed: 2026-02-24

Key Insights

• Beam Therapeutics continued to invest heavily in research and development, with R&D expenses increasing significantly year-over-year.
• The company expanded its collaboration with Pfizer and acquired Orbital Therapeutics, indicating continued growth and diversification of its pipeline.
• Beam Therapeutics reported increased cash and cash equivalents, strengthening its financial position to support future operations and development.

Sentiment: Positive Significance: 6/10

View Original Filing →

Current Report Filed: 2026-02-24

Key Insights

• Beam Therapeutics secured a $500 million senior secured term loan facility to support the development and commercialization of its lead drug candidate, risto-cel.
• The loan facility provides Beam with access to additional capital through several draw options, contingent on regulatory milestones and revenue targets for risto-cel.
• The financing agreement includes covenants and restrictions on Beam's business activities, such as limits on additional debt and licensing transactions for its core intellectual property.

Sentiment: Positive Significance: 8/10

View Original Filing →

Current Report Filed: 2026-02-12

Key Insights

• Beam Therapeutics has entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. to ensure continued access to certain patents in the event the existing license agreement between Bio Palette and Kobe University is terminated.
• The standby license agreement provides Beam Therapeutics with an exclusive license to the patents directly from Kobe University in certain scenarios, such as a termination of the existing agreement not due to Beam's breach.
• The financial terms of the standby license agreement include Beam Therapeutics paying Kobe University the amounts that would have been payable to Bio Palette under the existing license agreement.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-02-05

Key Insights

• Carole Ho, a member of Beam Therapeutics' Board of Directors, has resigned effective February 27, 2026. This change in leadership could signal a shift in the company's strategic direction or governance.
• The filing does not indicate any disagreement between Carole Ho and the company regarding its operations, policies, or practices, suggesting the resignation was amicable.
• As an 8-K filing, this report discloses a material event or change in the company's operations, which may be of interest to investors and analysts in evaluating Beam Therapeutics' current state and future prospects.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-01-26

Key Insights

• Bethany J. Cavanagh, SVP of Finance and Treasurer, sold 6,198 shares of Beam Therapeutics Inc. (BEAM) at a weighted average price of $35.0005 pursuant to a 10b5-1 trading plan adopted in September 2025.
• The insider sale represents a small portion (about 15%) of Cavanagh's total beneficial ownership of 34,813 shares in the company.
• The transaction was conducted in a planned and systematic manner, which may indicate Cavanagh's confidence in the company's near-term performance and valuation.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-01-26

Key Insights

• Christine Bellon, the Chief Legal Officer, sold 1,371 shares of Beam Therapeutics Inc. (BEAM) on January 22, 2026, reducing her direct beneficial ownership to 95,667 shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan that Bellon had adopted on September 16, 2025, suggesting pre-planned and regular insider transactions.
• Insider selling can sometimes signal management's belief that the stock is overvalued or the company's prospects are less favorable, though the context of the planned sale should be considered.

Sentiment: Neutral Significance: 5/10

View Original Filing →